JP2020512292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512292A5 JP2020512292A5 JP2019533167A JP2019533167A JP2020512292A5 JP 2020512292 A5 JP2020512292 A5 JP 2020512292A5 JP 2019533167 A JP2019533167 A JP 2019533167A JP 2019533167 A JP2019533167 A JP 2019533167A JP 2020512292 A5 JP2020512292 A5 JP 2020512292A5
- Authority
- JP
- Japan
- Prior art keywords
- delayed release
- linaclotide
- composition
- baseline
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003111 delayed effect Effects 0.000 claims description 67
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 claims description 47
- 229960000812 linaclotide Drugs 0.000 claims description 47
- 108010024409 linaclotide Proteins 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 44
- 239000007916 tablet composition Substances 0.000 claims description 43
- 208000004998 Abdominal Pain Diseases 0.000 claims description 33
- 229920000642 polymer Polymers 0.000 claims description 21
- 230000003442 weekly effect Effects 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 16
- 206010010774 Constipation Diseases 0.000 claims description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 13
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 13
- 210000001015 abdomen Anatomy 0.000 claims description 9
- 206010000060 Abdominal distension Diseases 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 206010060926 abdominal symptom Diseases 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 7
- 206010000059 abdominal discomfort Diseases 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000009505 enteric coating Methods 0.000 claims description 5
- 239000002702 enteric coating Substances 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000000116 mitigating effect Effects 0.000 claims description 4
- 230000002269 spontaneous effect Effects 0.000 claims description 4
- 238000009498 subcoating Methods 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021152 breakfast Nutrition 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 64
- 206010036772 Proctalgia Diseases 0.000 description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 3
- 229940127558 rescue medication Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010011796 Cystitis interstitial Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 208000019751 Anorectal disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061979 Genital pain Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010034310 Penile pain Diseases 0.000 description 1
- 206010036968 Prostatic pain Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010036775 Rectal inflammations Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022073214A JP2022093472A (ja) | 2016-12-21 | 2022-04-27 | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437566P | 2016-12-21 | 2016-12-21 | |
| US62/437,566 | 2016-12-21 | ||
| PCT/US2017/067814 WO2018119191A1 (en) | 2016-12-21 | 2017-12-21 | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022073214A Division JP2022093472A (ja) | 2016-12-21 | 2022-04-27 | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512292A JP2020512292A (ja) | 2020-04-23 |
| JP2020512292A5 true JP2020512292A5 (enrdf_load_stackoverflow) | 2021-02-04 |
Family
ID=61022424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533167A Pending JP2020512292A (ja) | 2016-12-21 | 2017-12-21 | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
| JP2022073214A Pending JP2022093472A (ja) | 2016-12-21 | 2022-04-27 | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022073214A Pending JP2022093472A (ja) | 2016-12-21 | 2022-04-27 | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 |
Country Status (10)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3140528A1 (en) * | 2019-06-10 | 2020-12-17 | Wilmin Bartolini | Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome |
| KR20240111797A (ko) * | 2021-11-29 | 2024-07-17 | 아이언우드 파마슈티컬스, 인코포레이티드 | 내장 통증의 치료를 위한 제약 조성물 |
| WO2023196821A2 (en) * | 2022-04-04 | 2023-10-12 | Thomas Jefferson University | Targeting neuropod cell gucy2c to control visceral pain and appetite |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| PL2328601T3 (pl) | 2008-08-15 | 2020-07-13 | Ironwood Pharmaceuticals, Inc. | Formulacje zawierające linaklotyd do podawania doustnego |
| EP2464373A1 (en) * | 2009-08-13 | 2012-06-20 | Ironwood Pharmaceuticals, Inc. | Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| PL2536742T3 (pl) | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
| ES2763404T3 (es) * | 2010-08-11 | 2020-05-28 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
| US9708371B2 (en) * | 2011-08-17 | 2017-07-18 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| BR112015016917B1 (pt) * | 2013-01-15 | 2022-08-30 | Ironwood Pharmaceuticals, Inc | Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| WO2016197042A1 (en) * | 2015-06-05 | 2016-12-08 | Ironwood Pharmaceuticals, Inc. | Modified or targeted release formulations of linaclotide |
-
2017
- 2017-12-21 BR BR112019012689-9A patent/BR112019012689A2/pt unknown
- 2017-12-21 MA MA047112A patent/MA47112A/fr unknown
- 2017-12-21 JP JP2019533167A patent/JP2020512292A/ja active Pending
- 2017-12-21 MX MX2019007574A patent/MX2019007574A/es unknown
- 2017-12-21 WO PCT/US2017/067814 patent/WO2018119191A1/en not_active Application Discontinuation
- 2017-12-21 CN CN201780087073.0A patent/CN110475564A/zh active Pending
- 2017-12-21 AU AU2017379082A patent/AU2017379082A1/en not_active Abandoned
- 2017-12-21 EP EP17833050.2A patent/EP3558337A1/en not_active Withdrawn
- 2017-12-21 EA EA201991531A patent/EA201991531A1/ru unknown
- 2017-12-21 CA CA3048195A patent/CA3048195A1/en active Pending
-
2019
- 2019-06-21 MX MX2023008839A patent/MX2023008839A/es unknown
-
2022
- 2022-04-27 JP JP2022073214A patent/JP2022093472A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| JP2017504590A5 (enrdf_load_stackoverflow) | ||
| JP2009501801A5 (enrdf_load_stackoverflow) | ||
| CN111918646B (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| JP2020503269A5 (enrdf_load_stackoverflow) | ||
| JP2020512292A5 (enrdf_load_stackoverflow) | ||
| HRP20250615T1 (hr) | Tradipitant za upotrebu u liječenju gastropareze | |
| CN111698992A (zh) | 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物 | |
| JP7651620B2 (ja) | 経口リファマイシンｓｖ組成物 | |
| JP2022093472A (ja) | リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法 | |
| JP2020500864A5 (enrdf_load_stackoverflow) | ||
| RU2017103511A (ru) | Способ обеспечения чувства сытости | |
| JP2024161048A (ja) | リナクロチドの改変または標的放出製剤 | |
| JP2020519576A5 (enrdf_load_stackoverflow) | ||
| US20230346878A1 (en) | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | |
| CA3131645A1 (en) | Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines | |
| TW201420103A (zh) | 包含左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及ｃｏｘ抑制劑之醫藥組合物於「依需求（ｏｎ ｄｅｍａｎｄ）」避孕之用途及應用療法 | |
| CN118541143A (zh) | 含有局部麻醉剂的胃滞留口服剂量单元 | |
| RU2793319C2 (ru) | Композиции рифамицина sv для перорального применения | |
| JPWO2020251923A5 (enrdf_load_stackoverflow) | ||
| WO2020120519A1 (en) | Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines | |
| EP4065129A1 (fr) | Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes | |
| RU2022106262A (ru) | Изделия и способы для введения терапевтических средств | |
| HK40017265A (en) | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide |